Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1310 - Lymphocytes express receptor tyrosine kinases in patients with renal cell carcinoma and healthy donors

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cancer Biology

Tumour Site

Renal Cell Cancer

Presenters

Ilya Tsimafeyeu

Citation

Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268

Authors

I. Tsimafeyeu1, M. Volkova2, A. Olshanskaia2, G. Raskin3, S. Aschuba4, Y. Khochenkova4, A. Bondarenko5, D. Khochenkov4

Author affiliations

  • 1 Moscow Office, Kidney Cancer Research Bureau, 105066 - Moscow/RU
  • 2 Dept. Of Urology, N.N. Blokhin Russian Cancer Research Center, Moscow/RU
  • 3 Dept. Of Pathology, A.M. Granov Russian Scientific Centre of Radiology and Surgical Technologies, Saint-Petersburg/RU
  • 4 Lab. Of Angiogenesis, N.N. Blokhin Russian Cancer Research Center, Moscow/RU
  • 5 Dept. Of General Medicine, I.M. Sechenov First Moscow State Medical University, Moscow/RU

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1310

Background

Very little is known about receptor tyrosine kinases (RTK) expression on peripheral blood mononuclear cells (PBMC) in humans including renal cell carcinoma (RCC) patients. The primary objective of study was to evaluate expression levels of major RTKs on PBMC and tumor infiltrating lymphocytes (TIL) isolated from RCC patients. The secondary aim was to compare levels of RTK expression in RCC patients before surgery and on the 180th day after surgery (lymphocyte lifetime) and to compare with expression in healthy donors (HD). In addition, we compared RTK and PD-L1 expression in TIL.

Methods

Tumor and blood samples were obtained from 20 patients with primary RCC immediately after surgical resection. Blood samples were collected from 10 HD. Tumors were harvested into RPMI1640 medium (Gibco) and processed within 4 h. TIL isolation was performed under modified protocol [Baldan 2015]. Isolated TIL and PBMC were prepared for flow cytometry. Cells were double stained with anti-CD45 FITC-conjugated mouse antibody and with PE-conjugated mouse antibodies to VEGFR1-2, PDGFRα-β, FGFR2 (all Sony Biotech) and were analyzed on NovoCyte 2000R flow cytometer (ACEA Biosciences). Expression of RTK was evaluated with NovoExpress Software. 20 tumors from same patients were stained with PD-L1 IHC assay (clone SP142 (Ventana).

Results

PBMC/TIL express RTKs (Table). In HD PBMC express all RTKs in 2-3 times higher than PBMC of RCC patients (all P < 0.05). TIL also had lower expression of RTK (all P < 0.05). There was no significant recovery of RTK expression on 180th day except of VEGFR2. Level of FGFR2 was lower on TIL (P = 0.03). 50% of patients had PD-L1 expression (1-11% of positive TIL). We found negative correlation of PDGFRα, β and PD-L1 expression (P = 0.04).Table: 27P

Expression of RTK, %, meanPBMC, HDPBMC, RCC, before surgeryPBMC, RCC, 180 days after surgeryTIL, RCC
VEGFR178.128.843.428.1
VEGFR279.627.157.844.3
PDGFRα80.144.949.152.3
PDGFRβ75.562.647.452.3
FGFR272.141.435.123.2

Conclusions

PBMC and TIL had similar low RTK expression levels in RCC patients. Lymphocytes of healthy humans had significantly higher expression of RTK. PD-L1 and PDGFRa-b expression could correlate.

Clinical trial identification

KCRB11022016.

Legal entity responsible for the study

Ministry of Health.

Funding

Kidney Cancer Research Bureau.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.